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Introduction
Venous thromboembolism (VTE) has been associated
with FMF but risk has not been studied in other auto
inflammatory syndromes. We therefore did a retrospec-
tive study of incidence of VTE in a cohort of patients
under Nottingham University Hospitals.
Objectives
To identify the incidence and site of VTE in patients with
auto inflammatory syndrome managed at our centre
from 1995 to 2013. In addition we sought to investigate
risk factors for VTE present, including laboratory evi-
dence of inflammation.
Methods
The case records of patients with auto inflammatory syn-
drome were studied to assess history and site of VTE. Sub-
type of auto inflammatory disease was noted along with
risk factors for VTE and therapy for auto inflammatory
disease. In addition it was assessed if auto inflammatory
disease had been clinically active at the time of VTE and
whether inflammatory markers were elevated in the
6 months prior to VTE. Mean and median values for high-
est CRP in the 6 months preceding the episodes of VTE
were calculated for the affected group.
Results
45 patients with auto inflammatory disease were included
in the study (22 with TRAPS, 2 with HIDS, 4 with FMF,
2 with CAPS, 1 with variant Schnitzler, 1 with NOD2
mutations and 13 undefined). 7 subjects (15.5% of cohort)
had a total of 11 episodes of VTE. This comprised 3 with
TRAPS, 1 with CINCA, 1 variant Schnitzler’s syndrome,
1 had auto inflammatory syndrome with NOD2 mutations
and granulomas and one undefined under investigation.
VTE included deep vein thrombosis (x 6), pulmonary
embolism (x 4) and Budd-Chiari syndrome (x 1). In those
with multiple VTE, recurrence of VTE occurred 1 to 2
months after discontinuation of anticoagulation.
Apart from underlying auto inflammatory disease no
risk factors for VTE were identified. 3 patients had throm-
bophilia screen which was negative excepting one patient
with low protein C presumed due to liver dysfunction. At
the time of VTE, all 7 patients were on prednisolone and
in addition 2 patients were on methotrexate, 1 on chlor-
ambucil and 1 on anakinra.
All patients reported recurrent flares or continuous
auto inflammatory symptoms prior to VTE. 6 out of
7 patients had raised CRP in the 6 months preceding
VTE. CRP values in the 6 months preceding VTE were
available for 10 episodes. The mean of the highest CRP
in the 6 months preceding each VTE episode was 119.8,
median was 124 with values ranging from 4 to 251.
3 patients are deceased. The 4 living patients are on
lifelong warfarin. Of note pleuritic chest pain was initially
attributed to flare of auto inflammatory disease and
responded partially to methyl prednisolone delaying diag-
nosis of pulmonary emboli.
Conclusion
In summary we report a high incidence of VTE in auto
inflammatory disease, particularly in the setting of uncon-
trolled inflammation. VTE may mimic symptoms of auto
inflammatory disease and needs to be considered to pre-
vent diagnostic delay. This cohort includes patients mana-
ged prior to availability of biological therapies and now
early introduction of biologicals to drive down acute phase
response may reduce risk of VTE. We also propose
whether VTE prophylaxis e.g. aspirin should be initiated
for patients with uncontrolled inflammation despite ther-
apy for auto inflammatory disease.
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